PBLS compared with ALMS: revenue, margins and what each company keeps, and the suppliers and customers both name

PBLSParabilis Medicines, Inc.

Mkt capRevenueRevenue

ALMSAlumis Inc.

Mkt capRevenueRevenue

Compare

PBLSParabilis Medicines, Inc.

ALMSAlumis Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PBLS1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−4.65%—

ALMS

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±25.3%▲+3.69%×0.15

May 15 '26±16.1%▼−7.15%×0.45

= impliedPBLS realized, solidALMS realized, hatchedOne scale, both sides: full bar = 26%× = |realized| ÷ impliedSource: market data

Q1 FY26

±20.4%

▼−1.26%

×0.06

Jan 9 '26±10.1%▲+7.59%×0.75

PBLSParabilis Medicines, Inc.

27.29▲+0.15%· post 29.29

Mkt cap$787.8MRevenue$148,000Q2 FY26Revenue—

ALMSAlumis Inc.

6.48▲+1.59%· post 6.48

ClosedNov 3 '26

Mkt cap$825.8MRevenue$2MQ2 FY26Revenue$24MFY25

Compare

ClosedNov 3 '26

PBLSParabilis Medicines, Inc.

ALMSAlumis Inc.

27.29▲+0.15%post 29.29

Price

6.48▲+1.59%post 6.48

$787.8M

Mkt cap

$825.8M

Q2 FY26$148,000

Revenue

$2MQ2 FY26

—

Revenue

$24MFY25

PBLS27.29▲+0.15%vsALMS6.48▲+1.59%ClosedNov 3 '26